Figure 4.

Effective vaccine-based clinical protection of MS patients irrespective of treatment regimen and satisfactory safety profile. (A) Comparison of probability of asymptomatic and symptomatic SARS-CoV-2 infection between OCR-pwMS, NAT-pwMS, S1P-pwMS, pwMS w/o DMT, and HC; (B) Comparison of side effects between OCR-pwMS, NAT-pwMS, S1P-pwMS, pwMS w/o DMT, and HC; (C) Correlation of number of side effects with age. Correlation analysis was performed with the Spearman correlation coefficient. The area in-between the dotted lines shows the 95% confidence interval. OCR, ocrelizumab; HC, controls without MS; MS, multiple sclerosis; n, no; NAT, natalizumab; SARS-CoV-2, severe acute respiratory syndrome; pwMS, patients with MS; S1P, sphingosine 1-phosphate receptor modulator; vacc., vaccination; w/o, without; y, yes.